Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) is a chronic and debilitating condition that results from severe inflammation of the gastrointestinal tract. Two conditions, ulcerative colitis and Crohn's disease, account for the vast majority of the 5 million IBD cases worldwide.
A growing body of scientific evidence suggest a causal link between the gut microbiome and IBD. A number of theories have been proposed implicating the microbiome in the pathogenesis of IBD. Ranging from the activation of the inflammasome through opportunistic pathogens that take advantage of barrier dysfunction to genetic defects within the host that trigger a deleterious response to normally commensal microbiota, the microbiome is central to the development of chronic intestinal inflammation and subsequent IBD.
Second Genome is actively investigating microbially-mediated mechanisms underlying IBD. By identifying the bacteria and viruses that play a role in IBD, our research team is aiming to identify new therapeutic approaches and strategies to treating this debilitating condition.
A significant body of research suggests that the microbiome is causal in the development of numerous metabolic disorders, including obesity and type 2 diabetes.
The worldwide prevalence of obesity and associated metabolic conditions continues to increase rapidly, impacting more than one in 5 Americans. Emerging evidence suggests that the microbiome is central to metabolic processes and redefines the way we understand this disease and its progression. Recent microbiome transplant studies have demonstrated that the introduction of specific microbes can influence host biology to drive weight loss or gain, suggesting the microbiome is an untapped source for the treatment of obesity. Leveraging our novel drug discovery platform, Second Genome can understand the unique biological interplay between the host and microbiomes to identify potential therapeutic targets to help curb the metabolic disease epidemic.